Is cyclic AMP formation desensitized in patients with end-stage renal failure?
1 Cyclic AMP formation has consistently been reported to be desensitized in various tissues including heart of animal models of end-stage renal failure (ESRF). In contrast, reports on desensitization of cAMP formation in ESRF patients remain contradictory. Whether this discrepancy results from a difference between human ESRF and its animal models or from the use of circulating blood cells in the human and various solid tissues in the animal studies, remains unclear. Therefore, we performed three studies with heart and platelets of ESRF patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis and age- and gender-matched controls with normal renal function (n = 11-13 each). 2 In platelets from haemodialysis patients adenylyl cyclase activity in response to receptor-dependent and -independent agonists was reduced by approximately 30%, and this could be explained by an alteration at the level of adenylyl cyclase itself. However, no such desensitization was seen in platelets from peritoneal dialysis patients. 3 In hearts from ESRF patients undergoing haemodialysis, beta-adrenoceptor density and subtype distribution, cAMP formation in response to the beta-adrenoceptor agonist isoprenaline or various receptor-independent stimuli, were very similar to those in control patients but activity of G-protein-coupled receptor kinase was increased by approximately 20%. 4 We conclude that conflicting reports on the desensitization of cAMP formation between ESRF patients and ESRF animal models are not explained by the use of solid tissues in animal studies vs. circulating blood cells in patient studies. Rather desensitization of cAMP formation seems to be a less consistent feature of human ESRF than of its animal models.
Leineweber
K
K
Department of Pathophysiology, University of Essen, Essen, Germany.
Schwiebert
C
C
Büscher
R
R
Michel
M C
MC
D000262:Adenylyl Cyclases / Q000097:blood; D020517:Atrial Appendage / Q000187:drug effects / Q000378:metabolism / Q000601:surgery; D001792:Blood Platelets / Q000737:chemistry / Q000378:metabolism; D002908:Chronic Disease; D000242:Cyclic AMP / Q000378:metabolism*; D004358:Drug Therapy / Q000379:methods; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods; D018342:Receptors, Adrenergic, beta-1 / Q000187:drug effects / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D006435:Renal Dialysis / Q000379:methods
D007093:Imidazoles; D018342:Receptors, Adrenergic, beta-1; D043562:Receptors, G-Protein-Coupled; C049763:CGP 20712A; D000242:Cyclic AMP; D000262:Adenylyl Cyclases